Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $116.9 million.

  • Celldex Therapeutics' Change in Acquisitions & Divestments fell 2119.61% to $116.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $638.8 million, marking a year-over-year increase of 5258.73%. This contributed to the annual value of $501.7 million for FY2024, which is 5649.37% up from last year.
  • Latest data reveals that Celldex Therapeutics reported Change in Acquisitions & Divestments of $116.9 million as of Q3 2025, which was down 2119.61% from $172.8 million recorded in Q2 2025.
  • Over the past 5 years, Celldex Therapeutics' Change in Acquisitions & Divestments peaked at $195.0 million during Q1 2025, and registered a low of $13.0 million during Q3 2021.
  • For the 5-year period, Celldex Therapeutics' Change in Acquisitions & Divestments averaged around $92.8 million, with its median value being $83.1 million (2023).
  • Within the past 5 years, the most significant YoY rise in Celldex Therapeutics' Change in Acquisitions & Divestments was 56238.46% (2022), while the steepest drop was 6430.13% (2022).
  • Over the past 5 years, Celldex Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $45.9 million in 2021, then skyrocketed by 91.09% to $87.8 million in 2022, then decreased by 19.26% to $70.9 million in 2023, then surged by 117.2% to $154.0 million in 2024, then dropped by 24.07% to $116.9 million in 2025.
  • Its Change in Acquisitions & Divestments was $116.9 million in Q3 2025, compared to $172.8 million in Q2 2025 and $195.0 million in Q1 2025.